a b s t r a c t
DiGeorge, or 22q11 deletion syndrome (22q11DS), the most common survivable human genetic deletion disorder, is caused by deletion of a minimum of 32 contiguous genes on human chromosome 22, and presumably results from diminished dosage of one, some, or all of these genes-particularly during development. Nevertheless, the normal functions of 22q11 genes in the embryo or neonate, and their contribution to developmental pathogenesis that must underlie 22q11DS are not well understood. Our data suggests that a substantial number of 22q11 genes act specifically and in concert to mediate early morphogenetic interactions and subsequent cellular differentiation at phenotypically compromised sites-the limbs, heart, face and forebrain. When dosage of a broad set of these genes is diminished, early morphogenesis is altered, and initial 22q11DS phenotypes are established. Thereafter, functionally similar subsets of 22q11 genes-especially those that influence the cell cycle or mitochondrial function-remain expressed, particularly in the developing cerebral cortex, to regulate neurogenesis and synaptic development. When dosage of these genes is diminished, numbers, placement and connectivity of neurons and circuits essential for normal behavior may be disrupted. Such disruptions likely contribute to vulnerability for schizophrenia, autism, or attention deficit/hyperactivity disorder seen in most 22q11DS patients. © 2010 ISDN. Published by Elsevier Ltd. All rights reserved.
22q11DS: a common and variable disorder of development
DiGeorge, or 22q11 deletion syndrome (22q11DS) is one of the most common "copy number variant" (CNV) genetic disorders currently known, occurring in an estimated 1/3000 live births (Shprintzen et al., 2005) . The dysmorphology common to many 22q11DS phenotypes-cardiovascular, craniofacial, limb malformations as well as thymic dysplasia-suggests that heterozygous deletion of the minimal 1.5 MB of chromosome 22 or the larger, more typical 3 MB deletion that includes this region; (Carlson et al., 1997) , and resulting diminished dosage of 22q11 genes, disrupts early development. Similarly, the significantly elevated susceptibility of 22q11DS patients for schizophrenia, autism, attention deficit/hyperactivity disorder (ADHD), language delay, and other behavioral disorders (Murphy et al., 1999; Niklasson et al., 2008) , all of which are thought to be "neurodevelopmental disorders" that compromise cerebral cortical circuitry (Geschwind and Levitt, 2007; Weinberger, 1987 Weinberger, , 1996 , suggests that 22q11DS disrupts brain development in parallel with peripheral and visceral morphogenesis.
Despite these obvious signs that diminished 22q11 gene dosage disrupts critical developmental mechanisms, little is known about how such changes in 22q11 gene function result in the constellation of 22q11DS phenotypes. Over the past 10 years, work from this laboratory and several others has defined some functions of individual 22q11 genes, and identified some consequences of diminished 22q11 gene dosage for cardiovascular, limb, craniofacial, and brain development (Merscher et al., 2001; Maynard et al., 2003; Meechan et al., 2009; Sigurdsson et al., 2010) . Our work suggests that 22q11 genes operate as functionally related "sets" at distinct times during development. Diminished dosage of a substantial set of 22q11 genes expressed at sites of mesenchymal/epithelial interaction-which later become the 22q11DS phenotypic sites-likely compromises early morphogenesis in the brain, face, heart and limbs. Subsequently, diminished dosage of a subset of these 22q11 genes-particularly those that regulate the cell cycle-disrupts neurogenesis in the cerebral cortex. Finally,
